TY  - JOUR
AU  - Sánchez-Gastaldo, Amparo
AU  - Muñoz-Fuentes, Miguel A
AU  - Molina-Pinelo, Sonia
AU  - Alonso-García, Miriam
AU  - Boyero, Laura
AU  - Bernabé-Caro, Reyes
PY  - 2021
DO  - 10.21037/tlcr-21-156
SN  - 2218-6751
UR  - https://hdl.handle.net/10668/27474
T2  - Translational lung cancer research
AB  - Immune checkpoint inhibitors (ICIs) are currently the standard therapy in advanced non-small cell lung cancer (NSCLC); however, there is no well-established prognostic biomarker. We investigated the relationship between survival outcomes and three...
LA  - en
KW  - Pembrolizumab
KW  - blood biomarkers
KW  - non-small cell lung cancer (NSCLC)
TI  - Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab.
TY  - research article
VL  - 10
ER  -